All Comments by Richard C. Mohs

  1. Plasma beta-amyloid 1-40 is associated with the diffuse small vessel disease subtype.
  2. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease.
  3. Parental history of Alzheimer disease associated with lower plasma apolipoprotein E levels.
  4. Familial Alzheimer's Disease Mutations in Presenilin 1 Do Not Alter Levels of the Secreted Amyloid-beta Protein Precursor Generated by beta-Secretase Cleavage.
  5. Assessing the relationship between health utilities, quality of life, and health care costs in Alzheimer's disease: the CATIE-AD study.
  6. Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration.
  7. Burden of Alzheimer's disease and association with negative health outcomes.
  8. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.
  9. Safety of lumbar puncture procedures in patients with Alzheimer's disease.
  10. Age, neuropathology, and dementia.
  11. Amyloid imaging in mild cognitive impairment subtypes.
  12. Association of prior stroke with cognitive function and cognitive impairment: a population-based study.
  13. Delirium accelerates cognitive decline in Alzheimer disease.
  14. Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid.
  15. A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain.